JP2023071729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023071729A5 JP2023071729A5 JP2023020373A JP2023020373A JP2023071729A5 JP 2023071729 A5 JP2023071729 A5 JP 2023071729A5 JP 2023020373 A JP2023020373 A JP 2023020373A JP 2023020373 A JP2023020373 A JP 2023020373A JP 2023071729 A5 JP2023071729 A5 JP 2023071729A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- human
- population
- protein
- recombinant expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 20
- 239000013604 expression vector Substances 0.000 claims 7
- 238000003259 recombinant expression Methods 0.000 claims 7
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000013598 vector Substances 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 2
- 230000001177 retroviral effect Effects 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 102000050320 human TNFRSF4 Human genes 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024118255A JP7739547B2 (ja) | 2017-06-30 | 2024-07-23 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2025146568A JP2025183273A (ja) | 2017-06-30 | 2025-09-03 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527556P | 2017-06-30 | 2017-06-30 | |
| US62/527,556 | 2017-06-30 | ||
| PCT/US2018/039917 WO2019006072A1 (en) | 2017-06-30 | 2018-06-28 | CHIMERIC ANTIGENIC RECEPTORS TO ANTIGEN OF MATURATION OF LYMPHOCYTES B WITH HUMAN DOMAINS |
| JP2019572798A JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572798A Division JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024118255A Division JP7739547B2 (ja) | 2017-06-30 | 2024-07-23 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023071729A JP2023071729A (ja) | 2023-05-23 |
| JP2023071729A5 true JP2023071729A5 (https=) | 2023-07-07 |
| JP7527419B2 JP7527419B2 (ja) | 2024-08-02 |
Family
ID=63350586
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572798A Active JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2023020373A Active JP7527419B2 (ja) | 2017-06-30 | 2023-02-13 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2024118255A Active JP7739547B2 (ja) | 2017-06-30 | 2024-07-23 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2025146568A Pending JP2025183273A (ja) | 2017-06-30 | 2025-09-03 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572798A Active JP7288405B2 (ja) | 2017-06-30 | 2018-06-28 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024118255A Active JP7739547B2 (ja) | 2017-06-30 | 2024-07-23 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
| JP2025146568A Pending JP2025183273A (ja) | 2017-06-30 | 2025-09-03 | ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200138865A1 (https=) |
| EP (2) | EP3645568B1 (https=) |
| JP (4) | JP7288405B2 (https=) |
| KR (2) | KR20250012203A (https=) |
| CN (1) | CN111094345B (https=) |
| AU (2) | AU2018291128B2 (https=) |
| ES (1) | ES2928296T3 (https=) |
| IL (1) | IL271597B2 (https=) |
| SG (1) | SG11201913175TA (https=) |
| WO (1) | WO2019006072A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| NZ725201A (en) | 2014-04-25 | 2018-05-25 | Bluebird Bio Inc | Improved methods for manufacturing adoptive cell therapies |
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| KR20240005168A (ko) | 2016-11-04 | 2024-01-11 | 2세븐티 바이오, 인코포레이티드 | 항-bcma car t 세포 조성물 |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| KR102752985B1 (ko) * | 2017-12-20 | 2025-01-10 | 포세이다 테라퓨틱스, 인크. | Vcar 조성물 및 사용 방법 |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| PL3823990T3 (pl) | 2018-07-20 | 2026-04-20 | TeneoTwo, Inc. | Przeciwciała łańcucha ciężkiego wiążące się z cd19 |
| CN113597328B (zh) | 2019-03-21 | 2025-10-31 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| JP2023518049A (ja) | 2020-03-16 | 2023-04-27 | ユニバーシティ オブ サザン カリフォルニア | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 |
| TWI838621B (zh) | 2020-04-29 | 2024-04-11 | 美商泰尼歐萬公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| AU2021263448B2 (en) | 2020-04-29 | 2026-02-05 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| IL299027A (en) | 2020-06-30 | 2023-02-01 | Teneobio Inc | Multispecific antibodies that bind BCMA |
| CA3200509A1 (en) | 2020-12-31 | 2022-07-07 | Sonja SCHREPFER | Methods and compositions for modulating car-t activity |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| BR112023024231A2 (pt) | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | Células t primárias rhd negativas hipoimunogênicas |
| AU2022283291A1 (en) | 2021-05-27 | 2023-11-02 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
| JP2024527539A (ja) * | 2021-07-01 | 2024-07-25 | 寧波茂行生物医薬科技有限公司 | ＩＬ１３Ｒα２を標的としたユニバーサルＣＡＲ－Ｔ細胞及びその製造方法と使用 |
| KR20240046319A (ko) | 2021-07-14 | 2024-04-08 | 사나 바이오테크놀로지, 인크. | 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현 |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| TW202321435A (zh) | 2021-08-11 | 2023-06-01 | 美商薩那生物科技公司 | 用於改變低免疫原性細胞中之基因表現之可誘導系統 |
| WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
| US20250059239A1 (en) | 2021-12-17 | 2025-02-20 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
| EP4448775A1 (en) | 2021-12-17 | 2024-10-23 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
| MX2024007528A (es) | 2021-12-23 | 2024-08-30 | Sana Biotechnology Inc | Linfocitos t del receptor de antígeno quimérico (car) para el tratamiento de enfermedades autoinmunitarias y métodos asociados. |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| KR20240155390A (ko) | 2022-02-17 | 2024-10-28 | 사나 바이오테크놀로지, 인크. | 조작된 cd47 단백질 및 이의 용도 |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN115851599B (zh) * | 2022-07-06 | 2026-03-17 | 上海优卡迪生物医药科技有限公司 | 一种用于治疗aml恶性肿瘤的cd38-car-t及其应用 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260098062A1 (en) | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| WO2024220598A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Lentiviral vectors with two or more genomes |
| EP4698666A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses |
| EP4698665A1 (en) | 2023-04-18 | 2026-02-25 | Sana Biotechnology, Inc. | Engineered protein g fusogens and related lipid particles and methods thereof |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025006799A1 (en) | 2023-06-27 | 2025-01-02 | Capstan Therapeutics, Inc. | Extracorporeal and ex vivo engineering of select cell populations from peripheral blood |
| AU2024328949A1 (en) | 2023-08-23 | 2026-03-12 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| GB202317065D0 (en) | 2023-11-07 | 2023-12-20 | Coding Bio Ltd | BCMA binding molecules |
| WO2025129201A1 (en) | 2023-12-15 | 2025-06-19 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
| WO2026072709A1 (en) | 2024-09-25 | 2026-04-02 | Orna Therapeutics, Inc. | Chimeric antigen receptors targeting bcma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA033110B1 (ru) | 2012-04-11 | 2019-08-30 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы |
| US20170081411A1 (en) * | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| MX2017001079A (es) | 2014-07-24 | 2017-09-12 | Bluebird Bio Inc | Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma). |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| EP4282877A3 (en) * | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| US11427642B2 (en) * | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| IL271194B2 (en) * | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
-
2018
- 2018-06-28 US US16/626,991 patent/US20200138865A1/en not_active Abandoned
- 2018-06-28 IL IL271597A patent/IL271597B2/en unknown
- 2018-06-28 KR KR1020257001390A patent/KR20250012203A/ko active Pending
- 2018-06-28 AU AU2018291128A patent/AU2018291128B2/en active Active
- 2018-06-28 WO PCT/US2018/039917 patent/WO2019006072A1/en not_active Ceased
- 2018-06-28 SG SG11201913175TA patent/SG11201913175TA/en unknown
- 2018-06-28 ES ES18759189T patent/ES2928296T3/es active Active
- 2018-06-28 EP EP18759189.6A patent/EP3645568B1/en active Active
- 2018-06-28 KR KR1020207002752A patent/KR102757010B1/ko active Active
- 2018-06-28 CN CN201880044208.XA patent/CN111094345B/zh active Active
- 2018-06-28 JP JP2019572798A patent/JP7288405B2/ja active Active
- 2018-06-28 EP EP22187063.7A patent/EP4159762A1/en active Pending
-
2023
- 2023-02-13 JP JP2023020373A patent/JP7527419B2/ja active Active
- 2023-11-30 US US18/524,799 patent/US12570717B2/en active Active
-
2024
- 2024-07-23 JP JP2024118255A patent/JP7739547B2/ja active Active
- 2024-10-29 AU AU2024227725A patent/AU2024227725A1/en active Pending
-
2025
- 2025-09-03 JP JP2025146568A patent/JP2025183273A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023071729A5 (https=) | ||
| JP2020529841A5 (https=) | ||
| JP6675417B2 (ja) | キメラ抗原受容体 | |
| ES2843599T3 (es) | Receptor de antígeno quimérico | |
| JP2022109953A5 (https=) | ||
| JP2021191265A5 (https=) | ||
| JPWO2020181094A5 (https=) | ||
| JP2021177771A5 (https=) | ||
| GB2611448A (en) | Polypeptide useful in adoptive cell therapy | |
| JP2023139070A5 (https=) | ||
| JP2019500848A5 (https=) | ||
| US20240101616A1 (en) | Dap10/12 based cars adapted for rush | |
| JP2019514361A5 (https=) | ||
| RU2022103665A (ru) | Химерные конструкции антитело/t-клеточный рецептор и их применения | |
| JP2020513754A5 (https=) | ||
| JP2018523484A (ja) | 細胞 | |
| JP2019535262A5 (https=) | ||
| JPH05501062A (ja) | Ｈｉｖ―１のウイルス性コンプレックス抗原に結合する組換え蛋白質 | |
| Romano et al. | Molecular cloning and characterization of CD4 in an aquatic mammal, the white whale Delphinapterus leucas | |
| JP2019530441A5 (https=) | ||
| JPWO2019155288A5 (https=) | ||
| WO2020253879A1 (zh) | 一种双特异性嵌合抗原受体 | |
| KR970070198A (ko) | 항-파스 재조합 항체 및 이에 대한 디엔아이 | |
| WO1997004109A1 (fr) | PROTEINES HETERO-MULTIMERIQUES RECOMBINANTES DU TYPE α - β C4BP | |
| JP2004535778A (ja) | ｈｄｍ２蛋白質―特異的なネズミα／βＴ−細胞受容体のポリペプチド、これらをコードする核酸およびそれらの使用 |